All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @loiskathrynxx on TikTok · 63s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @loiskathrynxx's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I saw us disregard a broken bottle of time
  2. 0:05And I want to thank God

@loiskathrynxx's GLP-1 progress claims, fact-checked

✨ Lois Kathryn ✨

TikTok creator

461.3K viewsWatch on TikTok

Quick answer

This video is categorized as GLP-1 content and framed as a personal weight-loss progression, but the transcript contains no direct medical claims, only lyrical audio. The clinical relevance lies in the implied context: GLP-1 receptor agonists like semaglutide and tirzepatide produce documented, significant weight reduction in clinical trials, making visible transformation content plausible and consistent with published outcomes. No specific drug, dose, or treatment protocol was stated or implied by the creator directly.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @loiskathrynxx's GLP-1 progress claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@loiskathrynxx's GLP-1 progress claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@loiskathrynxx's GLP-1 progress claims, fact-checked" from ✨ Lois Kathryn ✨. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video is categorized as GLP-1 content and framed as a personal weight-loss progression, but the transcript contains no direct medical claims, only lyrical audio.

The reason this review is not generic is the source wording and the canonical claim label "glp1 myprogression myjourney." In this clip, the useful excerpt is: "I saw us disregard a broken bottle of time And I want to thank God" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

SURMOUNT-1 (Jastreboff et al.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

This video is categorized as GLP-1 content and framed as a personal weight-loss progression, but the transcript contains no direct medical claims, only lyrical audio.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • This video is categorized as GLP-1 content and framed as a personal weight-loss progression, but the transcript contains no direct medical claims, only lyrical audio. The clinical relevance lies in the implied context: GLP-1 receptor agonists like semaglutide and tirzepatide produce documented, significant weight reduction in clinical trials, making visible transformation content plausible and consistent with published outcomes. No specific drug, dose, or treatment protocol was stated or implied by the creator directly.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide achieved up to 22.5% total body weight reduction at the highest dose, among the strongest results in the class.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide achieved up to 22.5% total body weight reduction at the highest dose, among the strongest results in the class.
  • GLP-1 medications require a prescription and ongoing clinical supervision. They are not available safely through unregulated channels.
  • Compounded semaglutide is not FDA-approved and cannot be treated as equivalent to brand-name Wegovy or Ozempic in terms of verified purity, potency, or safety.
  • Weight regain after stopping GLP-1 therapy is well-documented. Wilding et al. (2021) found participants regained roughly two-thirds of lost weight within a year of discontinuation.
  • GI side effects including nausea and vomiting affected more than 70% of participants at some point in the STEP trials. Progression content rarely acknowledges this.
  • This video made no direct medical claims. Fact-checking it requires addressing the implied context of GLP-1 transformation content rather than anything the creator explicitly stated.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @loiskathrynxx actually say?

Honestly? Almost nothing medically actionable. The transcript reads: "I saw us disregard a broken bottle of time And I want to thank God." That's it. This appears to be lyrical content, likely audio from a song playing over a weight-loss progression video, not a direct medical claim from the creator.

The hashtags tell us the context: #myprogression and #myjourney, filed under GLP-1 content. So the video is almost certainly a before-and-after transformation post tied to semaglutide, tirzepatide, or a similar GLP-1 receptor agonist. But the transcript itself contains no dosing advice, no drug recommendations, and no specific health claims. The words spoken belong to a song, not a medical monologue.

That matters for fact-checking purposes. We can assess what the video implies through its category and framing, but we can't hold the creator accountable for claims she didn't actually make out loud.

Does the science back this up?

The broader context here, GLP-1 progression content, is actually grounded in real clinical evidence. Before-and-after weight loss videos tied to GLP-1 medications aren't fabricated. These drugs work, and the data is solid.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide achieved up to 22.5% weight reduction in some participants. These are not trivial numbers. Visible, dramatic physical transformation over months of treatment is a documented, reproducible outcome.

So if this video shows a real person who lost significant weight on a GLP-1 medication and is expressing gratitude, that's entirely consistent with what clinical trials demonstrate. The emotional component, the thanksgiving, the sense of a life changed, also has support. Quality of life improvements are consistently reported in GLP-1 trial secondary endpoints.

What did they get wrong (or right)?

There's nothing factually wrong here because there are no factual claims. That's worth saying plainly: this creator did not give dosing advice, did not compare compounded drugs to brand-name versions, did not promise a cure. From a misinformation standpoint, this video is low risk.

What the video does right, implicitly, is present GLP-1 treatment as a personal journey with visible results. That framing is accurate to how these medications work for many patients. GLP-1 receptor agonists require sustained use, lifestyle integration, and medical supervision. A "my journey" framing is more honest than content that oversells instant results.

The one caution: before-and-after content on TikTok, even without explicit claims, can create unrealistic expectations. Wilding et al. (2021) noted that weight regain is common after discontinuation. The "progression" narrative rarely includes the part where stopping the medication often reverses much of the loss. That absence is not a lie, but it is an incomplete picture.

What should you actually know?

GLP-1 receptor agonists are legitimate, FDA-approved medications for weight management and type 2 diabetes. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have the strongest evidence bases among current options. Liraglutide and retatrutide are also in this class with varying approval statuses and evidence profiles.

What social media progression content rarely tells you: these medications require a prescription and ongoing clinical oversight. Side effects, primarily nausea, vomiting, and gastrointestinal discomfort, affect a significant portion of users. The STEP trials reported GI adverse events in over 70% of participants at some point during treatment.

Compounded versions of semaglutide have circulated widely during shortage periods, but compounded drugs are not FDA-approved and cannot be assumed equivalent to brand-name formulations in potency, purity, or safety. Anyone considering a GLP-1 treatment should go through a licensed medical provider, not a TikTok comment section.

Gratitude for a treatment that worked is human and real. But one person's dramatic result is not a guarantee. Individual response to GLP-1 medications varies based on genetics, adherence, baseline metabolic health, and other factors that a 60-second progression video cannot capture.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

✨ Lois Kathryn ✨ · TikTok creator

461.3K views on this video

#myprogression #myjourney

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?

The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed tirzepatide achieved up?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide achieved up to 22.5% total body weight reduction at the highest dose, among the strongest results in the class.

What does the video say about glp-1 medications require a prescription?

GLP-1 medications require a prescription and ongoing clinical supervision. They are not available safely through unregulated channels.

What does the video say about compounded semaglutide?

Compounded semaglutide is not FDA-approved and cannot be treated as equivalent to brand-name Wegovy or Ozempic in terms of verified purity, potency, or safety.

What does the video say about weight regain after stopping glp-1 therapy?

Weight regain after stopping GLP-1 therapy is well-documented. Wilding et al. (2021) found participants regained roughly two-thirds of lost weight within a year of discontinuation.

What does the video say about gi side effects including nausea?

GI side effects including nausea and vomiting affected more than 70% of participants at some point in the STEP trials. Progression content rarely acknowledges this.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ✨ Lois Kathryn ✨, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.